Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.
Approval Alert | Amivantamab/Chemotherapy in EGFR-Mutated NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
